(Q43973220)

English

Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice

scientific article published in May 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

inferred from title

author name string

Matthieu Gutman

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Steeve Couillard

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jenny Roy

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Fernand Labrie

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Bernard Candas

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Claude Labrie

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 May 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

273-278

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Mechanisms of antihormone action

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

The future of new pure antiestrogens in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Clinical potential of new antiestrogens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Epidemiology, prevention, and early detection of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Breast cancer prevention by antiestrogens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

The Estrogenic and Antiestrogenic Activities of Droloxifene in Human Breast Cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Selective oestrogen receptor modulation: molecular pharmacology for the millennium

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10302

21 January 2018

Identifiers

10.1002/IJC.10302

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43973220&oldid=2105179974"